Quan Chao, Lu Chuan-Zhen, Qiao Jian, Xiao Bao-Guo, Li X
Institute of Neurology, Huashan Hospital, Shanghai Medical College of Fudan University, 12 Wulumuqi Zhong Road, 200040, Shanghai, China.
J Clin Microbiol. 2006 Sep;44(9):3160-6. doi: 10.1128/JCM.00333-06.
Cerebrospinal fluid (CSF) and peripheral blood (PBL) were sampled multiple times from 25 patients with a clinical diagnosis of tuberculous meningitis (TBM) and 49 controls, including 27 patients with other infectious diseases of the central nervous system and 22 patients with other noninfectious neurological diseases. We used an enzyme-linked immunospot assay (ELISPOT) to detect anti-Mycobacterium bovis BCG antibody-secreting cells in CSF and PBL, PCR to detect a repeated insertion sequence (IS6110) specific for Mycobacterium tuberculosis in CSF, and an enzyme-linked immunosorbent assay (ELISA) to detect anti-BCG antibodies in CSF and PBL. In the meantime, culture of CSF from every TBM and control patient was done on Lowenstein-Jensen medium. ELISPOT proved to be the most valuable test, with a sensitivity of 84.0% and a specificity of 91.8%, and showed a sensitivity of 100.0% with the CSF specimens obtained within 4 weeks after the onset of TBM. The numbers of CSF anti-BCG immunoglobulin-secreting cells tested by ELISPOT were even higher in the early phase of TBM and declined while the disease was going on (P = 0.008), which allowed an early diagnosis to be made. The sensitivities of PCR and ELISA were only 75.0% and 52.3%, respectively; and the specificities were 93.7% and 91.6%, respectively. Culture of CSF on Lowenstein-Jensen medium was the least sensitive (16%) compared to the sensitivities of the other three assays. Our results demonstrate that the ELISPOT technique is worthy for routine use in the laboratory to support the clinical diagnosis of TBM.
从25例临床诊断为结核性脑膜炎(TBM)的患者和49例对照者中多次采集脑脊液(CSF)和外周血(PBL),49例对照者包括27例患有其他中枢神经系统感染性疾病的患者和22例患有其他非感染性神经系统疾病的患者。我们采用酶联免疫斑点试验(ELISPOT)检测CSF和PBL中分泌抗牛分枝杆菌卡介苗(BCG)抗体的细胞,采用聚合酶链反应(PCR)检测CSF中结核分枝杆菌特异的重复插入序列(IS6110),并采用酶联免疫吸附试验(ELISA)检测CSF和PBL中的抗BCG抗体。同时,将每位TBM患者和对照者的CSF接种于罗-琴培养基上进行培养。ELISPOT被证明是最有价值的检测方法,敏感性为84.0%,特异性为91.8%,对于TBM发病后4周内采集的CSF标本,其敏感性为100.0%。ELISPOT检测的CSF抗BCG免疫球蛋白分泌细胞数量在TBM早期更高,且随着病情进展而下降(P = 0.008),这有助于早期诊断。PCR和ELISA的敏感性分别仅为75.0%和52.3%;特异性分别为93.7%和91.6%。与其他三种检测方法的敏感性相比,CSF在罗-琴培养基上的培养敏感性最低(16%)。我们的结果表明,ELISPOT技术值得在实验室常规使用,以支持TBM的临床诊断。